The American Journal of Medicine
Volume 122, Issue 3 , Pages 273-280, March 2009

Elevated Body Mass Index and Use of Coronary Revascularization after Cardiac Catheterization

  • Kathryn M. King, RN, PhD

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Kathryn M. King, RN, PhD, Centre for Health and Policy Studies, Department of Community Health Sciences, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, Canada T2N 4N1
  • ,
  • Danielle A. Southern, MSc

      Affiliations

    • University of Calgary, Calgary, AB, Canada
  • ,
  • Jacques Cornuz, MD, MPH

      Affiliations

    • University Hospital, Lausanne, Switzerland
  • ,
  • Andrew Maitland, MB, FRCSC, FACS

      Affiliations

    • Calgary Health Region, Calgary, AB, Canada
  • ,
  • Merril L. Knudtson, MD

      Affiliations

    • Calgary Health Region, Calgary, AB, Canada
  • ,
  • William A. Ghali, MD, MPH

      Affiliations

    • University of Calgary, Calgary, AB, Canada

published online 23 January 2009.

Abstract 

Background

Obese persons suffer discrimination in society that may extend to health care use. We investigated whether overweight and obese patients are as likely to undergo coronary reperfusion or revascularization as patients of normal body weight.

Methods

Detailed clinical data were collected for an inception cohort of patients from Alberta, Canada, who underwent cardiac catheterization between April 2001 and March 2004. The patients' likelihood of receiving any revascularization, percutaneous coronary intervention, or coronary artery bypass graft surgery in the year after cardiac catheterization was examined on the basis of body mass index (BMI) grouping. Use of revascularization was examined separately for patients with high- and low-risk coronary disease.

Results

Of 27,460 patients who had BMI data recorded, 24% were of normal weight, 42% were overweight, and 35% were obese. Although overweight and obese patients were more likely to have percutaneous coronary intervention (adjusted hazard ratio [HR]=1.07, 95% confidence interval [CI], 1.01-1.12 and HR 1.08, 95% CI, 1.01-1.13, respectively), obese patients (BMI>30) were less likely to receive coronary artery bypass graft surgery (adjusted HR=0.93, 95% CI, 0.87-1.00). This was primarily because of less use of coronary artery bypass graft surgery for the most obese patients (obesity class III) with low-risk coronary anatomy (adjusted HR=0.61, 95% CI, 0.36-1.02).

Conclusion

The pattern of use of revascularization procedures after cardiac catheterization differs somewhat across BMI subgroups. These differences might be clinically appropriate, but they warrant further exploration.

Keywords: Access, Coronary revascularization, Obesity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: The Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease was initially funded with a grant from the W. Garfield Weston Foundation. The ongoing operation of this project has been made possible by operating grants from the Heart and Stroke Foundation of Alberta, Northwest Territories, and Nunavut, and the Canadian Institutes of Health Research, as well as support from the Canadian Cardiovascular Outcomes Research Team, a Canadian Institutes of Health Research-funded team grant initiative. The initiative also has received contributions from Alberta Health and Wellness, Merck Frosst Canada Inc, Monsanto Canada Inc-Searle, Eli Lilly Canada Inc, Guidant Corporation, Boston Scientific Ltd, Hoffmann-La Roche Ltd, and Johnson & Johnson Inc—Cordis. Dr King holds a Health Scholar Award from the Alberta Heritage Foundation for Medical Research. Dr Knudtson receives partial support from the Libin Trust Fund. Dr Ghali is supported by a Government of Canada Research Chair in Health Services Research and by a Senior Health Scholar Award from the Alberta Heritage Foundation for Medical Research.

 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this article.

 Authorship: All authors had access to the data and played a role in writing this article.

PII: S0002-9343(08)00985-6

doi:10.1016/j.amjmed.2008.09.036

The American Journal of Medicine
Volume 122, Issue 3 , Pages 273-280, March 2009